What is the primary purpose of the new Change in Control Severance Plan?

The primary purpose is to retain key employees by providing them with specific benefits and protections in the event of a change in control of the Company, thereby mitigating potential distractions and ensuring their continued focus on business operations.

Who is eligible to participate in this severance plan?

Officers and other executives of Regeneron designated in writing by the Compensation Committee are eligible. The Company's executive officers (excluding the President and CEO) are currently among the designated participants.

What are the typical benefits a participant would receive if their employment is terminated after a change in control?

If employment is terminated without cause (or if the participant resigns for good reason) within 24 months after or 6 months before a change in control, participants are entitled to cash severance (1x or 2x their annual base salary plus average bonus), a pro-rata bonus, and continued healthcare and welfare benefits for one or two years.

How are equity awards treated under this plan if there is a change in control?

In the event of an anticipatory termination (resignation for good reason or termination without cause) within six months prior to a change in control, equity awards that would have vested by the change in control date will become vested on that date. The exercise period for these awards may also be extended, subject to certain limitations.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 25, 2006, announcing the adoption of a Change in Control Severance Plan, effective February 1, 2006. This plan is designed to retain key employees and mitigate distractions during potential acquisition scenarios by providing severance benefits and accelerated equity vesting under specific termination circumstances following a change in control. The plan outlines benefits for eligible officers and executives, including cash severance, pro-rata bonuses, and continued healthcare coverage for a specified period. Importantly, it also addresses the treatment of equity grants in the event of an anticipatory termination, ensuring that certain awards vest upon a change in control. The plan is subject to administration, amendment, and termination provisions by the Board or Compensation Committee, with specific considerations for excise taxes to ensure compliance with Section 4999 of the Internal Revenue Code.

Key Highlights

1Regeneron adopted a Change in Control Severance Plan effective February 1, 2006.
2The plan aims to retain key employees and ensure focus during potential acquisition periods.
3Eligible participants include officers and executives designated by the Compensation Committee.
4Benefits include cash severance (1x or 2x base salary plus average bonus), pro-rata bonus, and continued healthcare coverage for 1-2 years.
5Equity grants (stock options, etc.) may vest upon a change in control if employment is terminated under specific circumstances.
6The plan requires participants to execute a release and agree to post-termination covenants (confidentiality, non-solicitation, cooperation).
7Provisions are included to limit payments to avoid 'golden parachute' excise taxes under Section 4999 of the Internal Revenue Code.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jan 25, 2006)

Summary

Key Highlights

Frequently Asked Questions